<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:chebi fb="0" ids="6541">Losartan</z:chebi> <z:chebi fb="120" ids="26216">potassium</z:chebi> (INN <z:chebi fb="0" ids="6541">losartan</z:chebi>), an <z:chebi fb="0" ids="35674">antihypertensive drug</z:chebi>, has been shown to prevent thoracic <z:hpo ids='HP_0004942'>aortic aneurysm</z:hpo> in <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> through the inhibition of transforming growth factor beta </plain></SENT>
<SENT sid="1" pm="."><plain>Recently we reported that <z:chebi fb="1" ids="50845">doxycycline</z:chebi>, a nonspecific inhibitor of matrix metalloproteinases 2 and 9, normalized aortic vasomotor function and suppressed <z:hpo ids='HP_0002617'>aneurysm</z:hpo> growth </plain></SENT>
<SENT sid="2" pm="."><plain>We hypothesized that a combination of <z:chebi fb="0" ids="6541">losartan</z:chebi> <z:chebi fb="120" ids="26216">potassium</z:chebi> and <z:chebi fb="1" ids="50845">doxycycline</z:chebi> would offer better secondary prevention treatment than would single-drug therapy to manage thoracic <z:hpo ids='HP_0004942'>aortic aneurysm</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: A well-characterized mouse model of <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> (Fbn1(C1039G/+)) was used </plain></SENT>
<SENT sid="4" pm="."><plain>At 4 months of age, when <z:hpo ids='HP_0002617'>aneurysm</z:hpo> had established, mice (n = 15/group) were given <z:chebi fb="1" ids="50845">doxycycline</z:chebi> alone (0.24 g/L), <z:chebi fb="0" ids="6541">losartan</z:chebi> <z:chebi fb="120" ids="26216">potassium</z:chebi> alone (0.6 g/L), or combined (0.12-g/L <z:chebi fb="1" ids="50845">doxycycline</z:chebi> and 0.3-g/L <z:chebi fb="0" ids="6541">losartan</z:chebi> <z:chebi fb="120" ids="26216">potassium</z:chebi>) in drinking water </plain></SENT>
<SENT sid="5" pm="."><plain>Littermate Fbn1(+/+) mice served as control </plain></SENT>
<SENT sid="6" pm="."><plain>Thoracic aortas at 6 and 9 months were studied </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: At 9 months, aortic diameter in untreated group was increased by 40% relative to control </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="6541">Losartan</z:chebi> <z:chebi fb="120" ids="26216">potassium</z:chebi> or <z:chebi fb="1" ids="50845">doxycycline</z:chebi> reduced aortic diameter by 10% to 16% versus untreated aortas </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="6541">Losartan</z:chebi> <z:chebi fb="120" ids="26216">potassium</z:chebi> and <z:chebi fb="1" ids="50845">doxycycline</z:chebi> combined completely prevented thoracic <z:hpo ids='HP_0004942'>aortic aneurysm</z:hpo> and improved elastic fiber organization, also downregulating matrix metalloproteinases 2 and 9 and transforming growth factor beta and normalizing aortic contractile and relaxation functions to control values </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Neither <z:chebi fb="0" ids="6541">losartan</z:chebi> <z:chebi fb="120" ids="26216">potassium</z:chebi> nor <z:chebi fb="1" ids="50845">doxycycline</z:chebi> alone completely restored vascular integrity and cell function when given during delayed treatment, indicating the importance of timed pharmacologic intervention </plain></SENT>
<SENT sid="11" pm="."><plain>Combined, however, they synergistically offered better <z:hpo ids='HP_0002617'>aneurysm</z:hpo>-suppressing effects than did single-drug medication in the secondary prevention of thoracic <z:hpo ids='HP_0004942'>aortic aneurysm</z:hpo> </plain></SENT>
</text></document>